Detalles de la búsqueda
1.
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
Diabetes Obes Metab
; 24(9): 1770-1778, 2022 09.
Artículo
Inglés
| MEDLINE | ID: mdl-35546790
2.
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
Diabetes Obes Metab
; 23(12): 2819-2824, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34463420
3.
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Diabetes Obes Metab
; 23(10): 2279-2288, 2021 10.
Artículo
Inglés
| MEDLINE | ID: mdl-34159708
4.
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
Diabetes Obes Metab
; 23(10): 2242-2250, 2021 10.
Artículo
Inglés
| MEDLINE | ID: mdl-34189841
5.
Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy.
Catheter Cardiovasc Interv
; 96(4): 793-801, 2020 10 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31721430
6.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions 2020 think tank.
Catheter Cardiovasc Interv
; 96(6): 1258-1265, 2020 11.
Artículo
Inglés
| MEDLINE | ID: mdl-32840956
7.
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
Muscle Nerve
; 61(1): 26-35, 2020 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31599456
8.
Cohort antler size signals environmental stress in a moderate climate.
Int J Biometeorol
; 64(4): 611-621, 2020 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-31900588
9.
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
Am Heart J
; 211: 68-76, 2019 05.
Artículo
Inglés
| MEDLINE | ID: mdl-30897527
10.
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Diabetes Obes Metab
; 21(9): 2048-2057, 2019 09.
Artículo
Inglés
| MEDLINE | ID: mdl-31050143
11.
Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
Am Heart J
; 205: 77-86, 2018 11.
Artículo
Inglés
| MEDLINE | ID: mdl-30196181
12.
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.
Circulation
; 129(4): 463-70, 2014 Jan 28.
Artículo
Inglés
| MEDLINE | ID: mdl-24281330
13.
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Lancet
; 382(9892): 614-23, 2013 Aug 17.
Artículo
Inglés
| MEDLINE | ID: mdl-23890998
14.
SCAI 2018 Think Tank Proceedings: "What should the role of the surgeon be in TAVR, both as a co-operator and in-patient evaluation for TAVR?
Catheter Cardiovasc Interv
; 93(1): 178-179, 2019 01 01.
Artículo
Inglés
| MEDLINE | ID: mdl-30358059
15.
Hot topics in interventional cardiology: Proceedings from the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Think Tank.
Catheter Cardiovasc Interv
; 94(4): 598-606, 2019 Oct 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31441590
16.
Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial.
Catheter Cardiovasc Interv
; 82(4): E365-74, 2013 Oct 01.
Artículo
Inglés
| MEDLINE | ID: mdl-22887494
17.
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES.
J Am Heart Assoc
; 12(1): e026482, 2023 01 03.
Artículo
Inglés
| MEDLINE | ID: mdl-36565189
18.
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
Breast Cancer Res Treat
; 134(1): 299-306, 2012 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-22484799
19.
Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program.
J Interv Cardiol
; 24(3): 232-40, 2011 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-21299633
20.
Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
J Interv Cardiol
; 24(4): 342-50, 2011 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-21492221